Neuralink

Company research

Public company, workplace, funding, and market signals

Updated Aug 5, 2026

Overview

Neuralink is a privately held biotechnology/neurotechnology company developing implantable brain-computer interfaces (BCIs) intended to translate neural activity into computer, robotic-arm, wheelchair, and eventually speech or vision commands. Its current work is investigational and centered on clinical trials for people with paralysis and ALS.

Primary product

N1 implant and associated Telepathy brain-computer-interface system, including a surgical robot and software that decode neural signals to control digital devices; investigational applications also include speech restoration, vision restoration (Blindsight), and mobility.

Founded

2016

Headquarters

Austin, Texas, United States

Team size

201-500 (public LinkedIn estimate; approximately 427)

Work style

Onsite

Industry

Biotechnology research

Sub-industry

Implantable brain-computer interfaces / neurotechnology / medical devices

Offices

Austin / Del Valle, Texas

South San Francisco, California

Fremont, California

Business model

Venture-funded R&D and clinical development

Future medical-device commercialization

Potential licensing, platform, and clinical-use revenue

Funding

Stage

Late-stage private company; Series E (with an additional 2026 Series E-II reported by CB Insights)

Total raised

$1.3B

Latest round

Series E-II · May 2026

Series E-II

May 2026 · Oman Investment Authority

Series E

Jun 2025 · Not publicly identified in Neuralink announcement; Reuters/Semafor reported Founders Fund involvement in the financing

$650M

Series D

Aug 2023 · Founders Fund

$280M

Earlier private rounds

People & investors

Leadership

Jared Birchall

Chief Executive Officer

DJ Seo

Co-founder, President & COO

Matthew MacDougall

Head of Surgery / Head Neurosurgeon

Kevin B.

Implant Firmware Team Lead

Grant Yoo

Research Team Leader

John W.F. To

Head of Brain Interfaces Materials

Lesley Chan

Microfabrication R&D Team Lead

Claire Castillo

Director of Technology Research and Development, Brain-Brain Interface

Founders

Benjamin Rapoport

Co-founder

Dongjin (DJ) Seo

Co-founder, President & COO

Elon Musk

Co-founder

Max Hodak

Co-founder; former President

Paul Merolla

Co-founder

Philip Sabes

Co-founder

Tim Hanson

Co-founder

Timothy J. Gardner

Co-founder

Vanessa Tolosa

Co-founder

Investors

Oman Investment Authority

Qatar Investment Authority

Valor Equity Partners

Vy Capital

Work & culture

The company describes an interdisciplinary, high-intensity environment emphasizing open communication, collaboration, transparency, first-principles problem solving, best ideas regardless of source, rapid advancement, and outsized individual impact. Public job materials suggest substantial onsite laboratory, manufacturing, surgery, and clinical work.

Work style

Onsite

Visa sponsorship

Yes

Compensation

Public job postings show base salary examples around $150,000-$281,000 for a Software Engineer, BCI Applications role, plus RSUs for full-time employees. Department of Labor-derived aggregators report H-1B filings and sponsored-role base salaries broadly around $80,000-$196,000 depending on role and location; these are signals, not guaranteed offers.

Benefits

Medical, dental, and vision PPO insurance

Paid holidays

Commuter benefits

Meals provided

Restricted stock units for full-time employees

401(k) plan

Parental leave

Flexible time off

Product & market

Pricing

No public commercial pricing; devices remain investigational and are not commercially available or FDA approved.

Differentiators

—Wireless implantable BCI with high channel count
—Flexible threads designed for minimally invasive robotic implantation
—Integrated implant, surgical robot, firmware, decoding software, and clinical-trial infrastructure
—Direct control of computers and physical devices by thought
—Ambition to expand from motor control to speech, vision, and whole-brain interfaces
—Rapid iteration using direct clinical-participant feedback

Technology

N1 implant

1,024-electrode neural interface

Flexible electrode threads

Neural-signal decoding and machine learning

Robotic implantation system

Implant firmware and embedded systems

Brain-computer-interface software

Microfabrication

Robotic arms and powered-wheelchair control

Speech-restoration and vision-restoration research

Customers

Clinical-trial participants with paralysis or ALS

Hospitals and clinical-trial institutions

Researchers and clinicians (future potential)

Competitors

Synchron

Blackrock Neurotech

Precision Neuroscience

Paradromics

Science Corporation

Neurable

Scale & contact

Estimated revenue

Approximately $20M-$30M annually (third-party LinkedIn/company-data estimate; not publicly reported financial revenue)

Signals & risks

Other

Neuralink's devices remain investigational, with regulatory approval and commercial-market access still unresolved; clinical and surgical risks remain material.

Source

Other

Feb 2025

Reuters reported that FDA employees involved in reviewing Neuralink and other BCI clinical-trial applications were among broader federal workforce cuts, potentially affecting regulatory-review continuity.

Source

Other

Jul 2026

Neuralink reported a new transdural implantation approach in a Canadian clinical trial; the approach is promising but remains early-stage and investigational.

Source

Latest news

Elon Musk Shows Off Neuralink Patients Navigating Wheelchairs By Thought Alone

Yahoo Tech · Jul 2026

Reported demonstrations in which participants used Neuralink signals to control powered wheelchairs; the system remains investigational.

Neuralink tests brain implant approach that leaves protective layer intact

ALS News Today · Jul 2026

The company reported a first human transdural procedure in Canada's CAN-PRIME trial, intended to simplify surgery and improve scalability.

Neuralink performs its first transdural implant on a Canadian ALS patient

Inside BCI · Jul 2026

Reported the first Canadian ALS participant and described expansion of Neuralink's international clinical-trial program.

Neuralink raises $650 million Series E

Neuralink · Jun 2025

Neuralink announced a $650M Series E and described five human pioneers, international clinical trials, and progress toward speech, vision, and broader brain-interface applications.

Musk's Neuralink raises fresh cash at $9 billion valuation, Semafor reports

Reuters · May 2025

Reuters reported a financing of approximately $600M at a roughly $9B pre-money valuation, based on Semafor reporting.

Careers Clinical trials Facebook LinkedIn company Official website Patient registry Speech-restoration trial Technology Updates / engineering-related publications X

SourcesNeuralink official website Neuralink careers Neuralink Series E announcement Neuralink LinkedIn company profile Reuters: 2023 funding Reuters: 2025 valuation and funding Neuralink Greenhouse job posting CB Insights funding profile

Jobs and careers at Neuralink

77 jobs at Neuralink

Contracts Manager

On-site

Legal

South San Francisco, California, United States

1w ago

On-site

Full-time